Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Receives Average Recommendation of “Moderate Buy” from Brokerages

Shares of Atara Biotherapeutics, Inc. (NASDAQ:ATRA) have been given an average recommendation of “Moderate Buy” by the seven ratings firms that are covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, two have issued a hold recommendation, three have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $17.75.

Several equities research analysts recently weighed in on ATRA shares. RODMAN&RENSHAW downgraded Atara Biotherapeutics from a “strong-buy” rating to a “hold” rating in a report on Tuesday, January 21st. Canaccord Genuity Group restated a “buy” rating and issued a $17.00 target price on shares of Atara Biotherapeutics in a research note on Tuesday, March 11th. Finally, HC Wainwright reiterated a “neutral” rating on shares of Atara Biotherapeutics in a research note on Tuesday, January 28th.

Atara Biotherapeutics Stock Performance

Shares of ATRA opened at $7.27 on Monday. Atara Biotherapeutics has a fifty-two week low of $5.01 and a fifty-two week high of $18.71. The firm has a 50-day simple moving average of $6.65 and a 200-day simple moving average of $9.25. The company has a market capitalization of $43.34 million, a price-to-earnings ratio of -0.28 and a beta of 0.30.

Atara Biotherapeutics (NASDAQ:ATRA) last posted its quarterly earnings data on Friday, March 7th. The biotechnology company reported ($1.19) EPS for the quarter, beating the consensus estimate of ($3.82) by $2.63. The company had revenue of $32.75 million for the quarter, compared to analysts’ expectations of $20.58 million. Equities research analysts forecast that Atara Biotherapeutics will post -10.39 EPS for the current year.

Institutional Investors Weigh In On Atara Biotherapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Point72 Asia Singapore Pte. Ltd. purchased a new stake in Atara Biotherapeutics during the fourth quarter worth $48,000. Cubist Systematic Strategies LLC purchased a new position in shares of Atara Biotherapeutics in the fourth quarter valued at $169,000. Citadel Advisors LLC raised its stake in shares of Atara Biotherapeutics by 2.6% during the 4th quarter. Citadel Advisors LLC now owns 267,353 shares of the biotechnology company’s stock worth $3,558,000 after buying an additional 6,873 shares during the last quarter. Bank of America Corp DE boosted its position in shares of Atara Biotherapeutics by 0.8% in the 4th quarter. Bank of America Corp DE now owns 205,170 shares of the biotechnology company’s stock worth $2,731,000 after buying an additional 1,543 shares in the last quarter. Finally, Northern Trust Corp purchased a new stake in shares of Atara Biotherapeutics in the 4th quarter worth about $149,000. 70.90% of the stock is currently owned by institutional investors and hedge funds.

Atara Biotherapeutics Company Profile

Atara Biotherapeutics, Inc engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.